Literature DB >> 28668178

Cholinergic symptoms and QTc prolongation following donepezil overdose.

A Pourmand1, C Shay2, W Redha3, A Aalam3, M Mazer-Amirshahi4.   

Abstract

Donepezil is the most commonly prescribed acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, an ailment that affects millions of older adult patients. By inhibiting the breakdown of acetylcholine in the central nervous system, donepezil has been shown to slow cognitive decline and improve patients' functional status. While donepezil is well-tolerated and generally considered safe at therapeutic doses, taking more than the prescribed dose could result in adverse cholinergic effects that range from mild gastrointestinal distress to serious cardiac dysrhythmias. We present a case of an 84-year-old man who developed gastrointestinal and cardiac disturbances after ingesting seven-times his daily dose of donepezil. As no specific antidote is available for donepezil overdose, this case highlights the importance of supportive care with particular attention to the management of cardiac dysrhythmias in patients displaying signs of toxicity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Bradycardia; Donepezil; QTc

Mesh:

Substances:

Year:  2017        PMID: 28668178     DOI: 10.1016/j.ajem.2017.06.044

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  3 in total

Review 1.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

2.  QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine.

Authors:  Katie Malone; Jules C Hancox
Journal:  Ther Adv Drug Saf       Date:  2020-08-17

3.  Donepezil-induced QTc prolongation: A case report.

Authors:  Samantha M Vogel; Lisa M Mican; Tawny L Smith
Journal:  Ment Health Clin       Date:  2019-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.